A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

Kimihiro Tanaka, Eriko Tokunaga, Nami Yamashita, Kenji Taketani, Sayuri Akiyoshi, Masaru Morita, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Purpose: The aim of the current study was to explore the efficacy and safety of combination therapy using a luteinizing hormone-releasing hormone (LHRH) agonist plus an aromatase inhibitor (AI) as second-line therapy in premenopausal females with hormone receptor (HR)-positive recurrent or metastatic breast cancer (MBC). Methods: A retrospective analysis was conducted in patients registered in the breast cancer database of our institution between January 2001 and December 2012. The breast cancer database identified 14 premenopausal patients who had been treated with an LHRH agonist plus AI for HR-positive recurrent or MBC. Results: Fourteen patients with recurrent breast cancer (N = 10) or metastatic disease at primary diagnosis (N = 4) were included in the present study. All patients had previously been treated with an LHRH agonist plus tamoxifen. The clinical benefit rate was 71.4 % and the median TTP was 11 months (95 % confidence interval 1.7-20.3 months). One patient discontinued treatment because of liver dysfunction (grade 3). Conclusions: The combination of an LHRH agonist plus an AI is a treatment option for premenopausal females with HR-positive MBC that can prolong the chemotherapy-free interval and yield effective disease stabilization.

Original languageEnglish
Pages (from-to)1678-1684
Number of pages7
JournalSurgery today
Volume44
Issue number9
DOIs
Publication statusPublished - Sep 2014

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint

Dive into the research topics of 'A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer'. Together they form a unique fingerprint.

Cite this